Cancer Biomarker Market Size, Share and Trends Report 2026 to 2035
What is Cancer Biomarker Market Size?
Global Cancer Biomarker Market Size was valued at USD 27.28 Bn in 2025 and is predicted to reach USD 41.47 Bn by 2035 at a 4.4% CAGR during the forecast period for 2026 to 2035.
Cancer Biomarker Market Size, Share & Trends Analysis Report, by Type of Biomarker (HER2, MET, EGFR, PD-L1, NTRK, ALK, Novel Biomarkers and Other Biomarkers), Type of Cancer (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, Thyroid Cancer, Bladder Cancer, Melanoma, Non-Hodgkins Lymphoma, Endometrial Cancer, Kidney Cancer and Leukemia), By Region, Forecasts, 2026 to 2035
Cancer Biomarker Market Key Takeaways:
|
The cancer biomarker market is witnessing rapid growth due to increasing cancer incidences and advancements in diagnostic technologies. Biomarkers like PSA, CA125, and BRCA1/2 are crucial for early detection, prognosis, and personalized treatment. Factors such as rising awareness, government initiatives, and investments in R&D are driving market expansion. Additionally, liquid biopsy techniques and next-generation sequencing are gaining prominence for non-invasive and accurate cancer diagnosis.
However, challenges like high costs, stringent regulatory frameworks, and limited specificity hinder market growth. Overall, the cancer biomarker market is poised for significant expansion, propelled by technological advancements and increasing demand for personalized medicine. The increasing incidence of cancer, followed by awareness for early diagnosis, growing investments in research and development of cancer biomarkers, and extensive use of these biomarkers for diagnosis, drug discovery, and development are the key factors for the growth of this market. The COVID-19 pandemic adversely impacted the cancer biomarker market, causing disruptions in supply chains, delayed diagnosis and treatment, and reduced healthcare access. However, the market showed resilience with increased focus on research for COVID-19-related biomarkers and a shift towards telemedicine and remote patient monitoring, driving digital biomarker adoption.
Competitive Landscape
Some of the Major Key Players in the Cancer Biomarker Market are
- Agilent
- ARUP Laboratories
- BioReference
- Foundation Medicine
- OncoDNA
- Q² Solutions
- Thermo Fisher Scientific
- YuceBio
- Asper Biogene
- Caris Life Sciences
- CeGaT
- Genekor Medical
- Guardant Health
- Labcorp
- MedGenome
- NeoGenomics Laboratories
- Nonacus
- Oxford Gene Technology
- Personal Genome Diagnostics
- PhenoPath
- Positive Biosciences
- Quest Diagnostics
- Tempus
Market Segmentation:
In the cancer biomarker market, segmentation is based on the type of biomarkers and type of cancers. Biomarkers type segmentation includes Human Epidermal Growth Factor Receptor 2 (HER2), Mesenchymal Epithelial Transition (MET), Epidermal Growth Factor Receptor (EGFR), Programmed Death-Ligand 1 (PD-L1), Neurotrophic Tyrosine Receptor Kinase (NTRK), Anaplastic Lymphoma Kinase (ALK) and Other Biomarkers. The types of cancers include breast cancer, prostate cancer, colorectum cancer, lung cancer, thyroid cancer, bladder cancer, melanoma, non-Hodgkin lymphoma, endometrial cancer, kidney cancer, and leukemia.
Based on Biomarkers, the HER2(Human Epidermal Growth Factor Receptor 2 Segment is Accounted as a Major Contributor in the Market
The HER2 segment in the cancer biomarker market is a key area of focus, particularly in breast cancer diagnostics and treatment. HER2 is overexpressed in around 20% of breast cancers, making it a critical biomarker for prognosis and targeted therapy. The development of HER2-targeted therapies like trastuzumab has significantly improved patient outcomes. Continuous research in HER2 detection methods and personalized treatment strategies further drives growth in this segment.
Breast Cancer Biomarkers Segment Witnessed Growth at a Rapid Rate.
The breast cancer biomarker segment is pivotal in early detection, prognosis, and personalized treatment of breast cancer. Additionally, novel biomarkers such as circulating tumor DNA (ctDNA) and microRNAs are being explored for their potential to improve diagnostic accuracy and monitor treatment response.
In the Region, the North American Cancer Biomarker Market Holds a Significant Revenue Share.
The North America cancer biomarker market is expected to register the highest market share. It can be due to its pharmaceutical industry and technological advancements. Additionally, North America has witnessed a tremendous increase in the adoption of biomarker testing for oncological disorders. The presence of a skilled workforce, advanced infrastructure, and a favorable business environment further results in the region's growth in the cancer biomarker market.
In addition, Asia Pacific is estimated to grow at a rapid rate in the global Cancer Biomarker Market due to growing concerns about rapid industrialization, government initiatives, and increasing funding in various industries.
Recent Developments
- In November 2023, Agilent received FDA approval for PD-L1 IHC 22C3 pharmDx in gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- In December 2022, QIAGEN received FDA approval for a companion diagnostic to Mirati Therapeutics' KRAZATI in non-small cell lung cancer.
- In November 2022, Biocare Medical, a leading provider of innovative, automated immunohistochemistry (IHC) and FISH (Fluorescent in situ hybridization) instrumentation and reagents, acquired Empire Genomics, a market leader in molecular biomarkers to aid in cancer research and diagnostics.
- In May 2022, Illumina introduced a new pan-cancer companion diagnostic to match patients with rare genetic mutations to targeted therapy.
Cancer Biomarker Market Report Scope :
| Report Attribute | Specifications |
| Market Size Value In 2025 | USD 27.28 Bn |
| Revenue Forecast In 2035 | USD 41.47 Bn |
| Growth Rate CAGR | CAGR of 4.4% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Type of Biomarkers, Type of Cancer |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; Southeast Asia; South Korea |
| Competitive Landscape | Agilent, ARUP Laboratories, BioReference, Foundation Medicine, OncoDNA, Q² Solutions, Thermo Fisher Scientific, YuceBio, Asper Biogene, Caris Life Sciences, CeGaT, Genekor Medical, Guardant Health, Labcorp, MedGenome, NeoGenomics Laboratories, Nonacus, Oxford Gene Technology, Personal Genome Diagnostics, PhenoPath, Positive Biosciences, Quest Diagnostics, and Tempus. |
| Customization Scope | Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of Cancer Biomarker Market :
Cancer Biomarker Market, By Type of Biomarkers-
- HER2
- MET
- EGFR
- PD-L1
- NTRK
- ALK
- Novel Biomarkers
- Other Biomarkers
Cancer Biomarker Market, By Type of Cancer-
- Breast Cancer
- Prostate Cancer
- Colorectum Cancer
- Lung Cancer
- Thyroid Cancer
- Bladder Cancer
- Melanoma
- Non-Hodgkins Lymphoma
- Endometrial Cancer
- Kidney Cancer
- Leukemia
- Others
Cancer Biomarker Market, By Region-
- North America-
- The US
- Canada
- Europe-
- Germany
- The UK
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific-
- China
- Japan
- India
- South Korea
- South East Asia
- Rest of Asia Pacific
- Latin America-
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Middle East & Africa-
- GCC Countries
- South Africa
- Rest of Middle East and Africa
Research Design and Approach
This study employed a multi-step, mixed-method research approach that integrates:
- Secondary research
- Primary research
- Data triangulation
- Hybrid top-down and bottom-up modelling
- Forecasting and scenario analysis
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary Research
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Sources Consulted
Secondary data for the market study was gathered from multiple credible sources, including:
- Government databases, regulatory bodies, and public institutions
- International organizations (WHO, OECD, IMF, World Bank, etc.)
- Commercial and paid databases
- Industry associations, trade publications, and technical journals
- Company annual reports, investor presentations, press releases, and SEC filings
- Academic research papers, patents, and scientific literature
- Previous market research publications and syndicated reports
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary Research
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Stakeholders Interviewed
Primary interviews for this study involved:
- Manufacturers and suppliers in the market value chain
- Distributors, channel partners, and integrators
- End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
- Industry experts, technology specialists, consultants, and regulatory professionals
- Senior executives (CEOs, CTOs, VPs, Directors) and product managers
Interview Process
Interviews were conducted via:
- Structured and semi-structured questionnaires
- Telephonic and video interactions
- Email correspondences
- Expert consultation sessions
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
Data Processing, Normalization, and Validation
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
- Standardization of units (currency conversions, volume units, inflation adjustments)
- Cross-verification of data points across multiple secondary sources
- Normalization of inconsistent datasets
- Identification and resolution of data gaps
- Outlier detection and removal through algorithmic and manual checks
- Plausibility and coherence checks across segments and geographies
This ensured that the dataset used for modelling was clean, robust, and reliable.
Market Size Estimation and Data Triangulation
Bottom-Up Approach
The bottom-up approach involved aggregating segment-level data, such as:
- Company revenues
- Product-level sales
- Installed base/usage volumes
- Adoption and penetration rates
- Pricing analysis
This method was primarily used when detailed micro-level market data were available.
Top-Down Approach
The top-down approach used macro-level indicators:
- Parent market benchmarks
- Global/regional industry trends
- Economic indicators (GDP, demographics, spending patterns)
- Penetration and usage ratios
This approach was used for segments where granular data were limited or inconsistent.
Hybrid Triangulation Approach
To ensure accuracy, a triangulated hybrid model was used. This included:
- Reconciling top-down and bottom-up estimates
- Cross-checking revenues, volumes, and pricing assumptions
- Incorporating expert insights to validate segment splits and adoption rates
This multi-angle validation yielded the final market size.
Forecasting Framework and Scenario Modelling
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Forecasting Methods
- Time-series modelling
- S-curve and diffusion models (for emerging technologies)
- Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
- Price elasticity models
- Market maturity and lifecycle-based projections
Scenario Analysis
Given inherent uncertainties, three scenarios were constructed:
- Base-Case Scenario: Expected trajectory under current conditions
- Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
- Conservative Scenario: Slow adoption, regulatory delays, economic constraints
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.
Request Customization
Add countries, segments, company profiles, or extend forecast — free 10% customization with purchase.
Customize This Report →Enquire Before Buying
Speak with our analyst team about scope, methodology, pricing, or deliverable formats.
Enquire Now →Frequently Asked Questions
Cancer Biomarker Market Size was valued at USD 27.28 Bn in 2025 and is predicted to reach USD 41.47 Bn by 2035
Cancer Biomarker Market is predicted to develop at a 4.4% CAGR during the forecast period for 2026 to 2035
Agilent, ARUP Laboratories, BioReference, Foundation Medicine, OncoDNA, Q² Solutions, Thermo Fisher Scientific, YuceBio, Asper Biogene, Caris Life Sciences, CeGaT, Genekor Medical, Guardant Health, Labcorp, MedGenome, NeoGenomics Laboratories, Nonacus, Oxford Gene Technology, Personal Genome Diagnostics, PhenoPath, Positive Biosciences, Quest Diagnostics, Tempus and Other
Cancer Biomarker Market is segmented into Type of Biomarkers, Type of Cancer and Other.
North America region is leading the Cancer Biomarker Market